Acadia Pharmaceuticals (ACAD) PT Raised to $32 at BofA Securities
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $27.83 +0.32%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Join SI Premium – FREE
BofA Securities analyst Tazeen Ahmad raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $32.00 (from $28.00) while maintaining a Neutral rating.
You May Also Be Interested In
- JPMorgan Downgrades Bukit Asam Tbk PT (PTBA:IJ) to Underweight
- Linde (LIN) PT Lowered to $563 at Bernstein SocGen Group
- Oracle (ORCL) PT Lowered to $200 at Stifel, Buy Rating Maintained
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
